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Reduced hepatitis B and D viral 
entry using clinically applied drugs 
as novel inhibitors of the bile acid 
transporter NTCP
Joanne M. Donkers1, Benno Zehnder  2, Gerard J. P. van Westen3, Mark J. Kwakkenbos4, 
Adriaan P. IJzerman  3, Ronald P. J. Oude Elferink1,5, Ulrich Beuers1,5, Stephan Urban2,6 & 
Stan F. J. van de Graaf  1,5
The sodium taurocholate co-transporting polypeptide (NTCP, SLC10A1) is the main hepatic transporter 
of conjugated bile acids, and the entry receptor for hepatitis B virus (HBV) and hepatitis delta virus 
(HDV). Myrcludex B, a synthetic peptide mimicking the NTCP-binding domain of HBV, effectively blocks 
HBV and HDV infection. In addition, Myrcludex B inhibits NTCP-mediated bile acid uptake, suggesting 
that also other NTCP inhibitors could potentially be a novel treatment of HBV/HDV infection. This study 
aims to identify clinically-applied compounds intervening with NTCP-mediated bile acid transport and 
HBV/HDV infection. 1280 FDA/EMA-approved drugs were screened to identify compounds that reduce 
uptake of taurocholic acid and lower Myrcludex B-binding in U2OS cells stably expressing human NTCP. 
HBV/HDV viral entry inhibition was studied in HepaRG cells. The four most potent inhibitors of human 
NTCP were rosiglitazone (IC50 5.1 µM), zafirlukast (IC50 6.5 µM), TRIAC (IC50 6.9 µM), and sulfasalazine 
(IC50 9.6 µM). Chicago sky blue 6B (IC50 7.1 µM) inhibited both NTCP and ASBT, a distinct though related 
bile acid transporter. Rosiglitazone, zafirlukast, TRIAC, sulfasalazine, and chicago sky blue 6B reduced 
HBV/HDV infection in HepaRG cells in a dose-dependent manner. Five out of 1280 clinically approved 
drugs were identified that inhibit NTCP-mediated bile acid uptake and HBV/HDV infection in vitro.
The sodium taurocholate co-transporting polypeptide (NTCP, SLC10A1) plays a pivotal role in the enterohepatic 
circulation of bile acids as the main uptake transporter of conjugated bile acids in the liver1. NTCP is exclu-
sively expressed at the basolateral membrane of hepatocytes, where it extracts bile acids from the portal vein 
in a sodium-dependent manner. Recently, NTCP was identified as the entry receptor for the hepatitis B virus 
(HBV)2,3. Viral infection with Hepatitis B causes acute and chronic inflammation of the liver and is one of the 
major infectious diseases worldwide4. Chronic HBV infection is nowadays treated by interferon-alpha or nucle-
oside/nucleotide analogues but this rarely results in viral elimination. On top of HBV infection, it is estimated 
that 5% of HBV patients suffer from a co- or superinfection of the related hepatitis delta virus (HDV)5–7. This 
RNA virus propagates only in HBV infected cells as HBV-encoded envelope proteins are utilized for HDV envel-
opment. For HDV no antiviral treatment is available. Furthermore, recent data show that NTCP also plays a 
modulatory role in hepatitis C virus (HCV) host cell infection and cell to cell transmission by bile-acid-mediated 
regulation of antiviral responses of the innate immune system8.
HBV/HDV binding to the NTCP protein on the host cell is mediated by the myristoylated preS1-domain 
of the HBV envelope L-protein9. Myrcludex B, a synthetic peptide mimicking the HBV-specific NTCP-binding 
domain10, strongly interferes with viral docking and therefore abrogates HBV/HDV infection in established cell 
culture models of HBV/HDV infection11,12. Currently, Myrcludex B is being tested in phase II clinical trials as 
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a novel means to inhibit HBV/HDV entry13–16. Largely reduced HDV RNA and HBV DNA serum levels were 
detected in a cohort of chronic hepatitis delta patients treated with Myrcludex B for 24 weeks13.
Upon NTCP inhibition by Myrcludex B, bile acid transport is affected17. However, whether NTCP inhibition 
can also affect drug exposure or clearance is unknown. Therefore we formulated the following three research 
questions. First, can we identify clinically applied and licenced drugs as novel NTCP inhibitors? Second, and in 
the context of drug-drug interaction, do such drugs compete with Myrcludex B for NTCP and vice versa? Third, 
can these novel NTCP inhibitors reduce HBV/HDV infection in vitro? In two screening approaches we evaluated 
1280 clinically approved drugs on interference with NTCP-mediated bile acid transport and on occupation of the 
Myrcludex B binding site of NTCP. As a result, we describe the identification of 5 novel NTCP inhibitors with an 
estimated IC50 value below 10 µM that reduce HBV/HDV infection in HepaRG cells in a dose-dependent manner.
Results
Identification of novel NTCP inhibitors. To find novel NTCP inhibitors, 1280 drugs were screened at 
a concentration of 10 µM (Fig. 1A). Therefore, two screening strategies using U2OS cells stably transfected with 
human NTCP were combined. Since U2OS cells do not express endogenous bile acid transporter proteins NTCP-
independent taurocholate uptake activity is minimal18,19. Screening quality was assessed by defining the z-factor 
for each screening plate20, continuing data analysis for plates of a z-factor between 0.5–1.0. NTCP inhibition was 
acknowledged to a drug if taurocholate uptake or Myrcludex B-FITC fluorescence was decreased with at least 75% 
compared to the control. For each compound two B scores were calculated (Fig. 1B and Supplementary Table S1), 
which is a statistical score that shows the relative potency of a candidate within the studied population21. Amongst 
the top 150 hits, our screen identified bile acids (litocholic acid, chenodeoxycholic acid, ursodeoxycholic acid) 
(Fig. 1B, green dots) and drugs that had been described earlier as NTCP inhibitors (cyclosporin A, irbesartan, 
ezetimibe, pioglitazone22–26) (Fig. 1B, blue dots), which provided validation of both screening methods. From 
the top 30 we selected our hits, but we excluded bile acids and previously described NTCP inhibitors, as well as 
compounds inducing apoptosis or described as being hepatotoxic. We further narrowed down the remaining list 
of compounds by selecting one drug from a cluster of two or more drugs with a similar structure and/or mecha-
nistic action, e.g. zafirlukast, pranlukast and montelukast. This resulted in a total of ten candidates selected from 
the lower-left quadrant for follow-up analysis: chicago sky blue 6B, flufenamic acid, nelfinavir mesylate hydrate, 
nifedipine, rosiglitazone, sulfasalazine, tolfenamic acid, toltrazuril, TRIAC, and zafirlukast (Fig. 1B red dots). 
Additionally, two compounds were selected that were only identified in one of the two screens: amlexanox (TC 
uptake screen) and hydroxytacrine maleate (Myrcludex B binding assay). Follow-up screening proved them to be 
false positives, demonstrating the effectiveness of using overlapping data from two different/orthogonal assays 
for compound selection.
Figure 1. Screening approach and results. (A) Flow diagram of the approach to identify drugs that inhibit 
human NTCP. (B) B-scores for each compound of the two screening assays are depicted with inhibition of 
uptake present in the lower quadrants and inhibition of Myrcludex B binding in the left quadrants. Each 
dot represents a compound, with bile acids in green, previously known NTCP-inhibitors in blue, and the 
compounds selected for further analysis in red.
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In vitro validation of selected overlapping top-hits. Five out of twelve selected compounds inhibited 
NTCP in repeated measurements of TC-uptake and Myrcludex B binding at concentrations of ≤ 10 µM: chicago 
sky blue 6B, rosiglitazone, sulfasalazine, TRIAC, and zafirlukast (Table 1). Inhibition was measured and IC50 val-
ues were calculated from increasing concentrations, ranging from 1 nM to 10 mM. Zafirlukast was one of the most 
potent inhibitors with an IC50 value of 6.5 µM (Fig. 2A and B) and more than 50% decreased Myrcludex B binding 
at 10 µM (Fig. 2C and D). Figure 3 shows the inhibitory effects of chicago sky blue 6B, rosiglitazone, sulfasala-
zine, and TRIAC on NTCP-mediated TC uptake and Mycludex B binding. Flufenamic acid and tolfenamic acid 
had an IC50 value of 10 and 12.5 µM respectively, and both decreased Myrcludex B binding to NTCP with 50% 
at ≤ 100 µM. Selected compounds with lower affinity were not included in further experiments (Supplementary 
Figures S1 and S2).
Myrcludex B inhibits uptake of tauro-ursodeoxycholic acid. Ursodeoxycholic acid (UDCA), an 
unconjugated bile acid frequently used as treatment in cholestatic conditions, was found among the top 100 
best hits (Supplementary Table S1). Indeed, sodium-dependent uptake of tauro-ursodeoxycholic acid is largely 
inhibited upon treatment with Myrcludex B (Fig. 4) as described before for taurocholic acid (IC50 52,5 nM)24. This 
indicates that therapeutic co-administration of Myrcludex B at NTCP saturating conditions with UDCA might 
affect the pharmacokinetics of UDCA and vice versa. Of note, Myrcludex B effectively inhibits HBV/HDV infec-
tion at concentrations (83 pM for HBeAg in primary human hepatocytes24), where NTCP-mediated transport 
of substrates is not yet affected. From the other compounds that reduced NTCP activity (b-score ≤−5) frequent 
clinical co-application with Myrcludex B, and thus possibly drug-drug interaction, is not anticipated.
Drug cytotoxicity. Drug cytotoxicity was examined for each compound at three concentrations. In 
U2OS-HA-hNTCP cells, viability was above 80% for all drugs at the two lowest concentrations (Supplementary 
Table S2). At 100 µM, nifedipine and zafirlukast exerted minor cytotoxicity, with a cell viability of 71.5 ± 7.3% and 
77.7 ± 8.0% respectively. Similar cell viability results were obtained in U2OS-HA-hNTCP and in wildtype U2OS 
cells (Supplementary Table S2).
Inhibition of HBV and HDV infection. Since several NTCP inhibitors, e.g. irbesartan and cyclosporin A, 
have been shown to affect HBV and HDV infection22–25,27, we tested the 5 strongest hits from our screen in this 
experimental setting as well for interference with HBV/HDV infection. To that aim HepaRG cells were infected 
with HBV or HDV and viral markers HBsAg, HBeAg and intracellular HBcAg/HDAg were quantified. Myrcludex 
B and irbesartan were included as positive controls for infection inhibition. As depicted in Fig. 5A and B, produc-
tion of both HBeAg and HBsAg was significantly reduced for all compounds in a concentration-dependent man-
ner. Zafirlukast, chicago sky blue 6B and irbesartan were effective at 17 µM, whereas rosiglitazone, sulfasalazine, 
and TRIAC which were only effective in reducing HBsAg at concentrations of ≥50 µM. Higher concentrations 
of the drugs established a further reduction in HBeAg and HBsAg. Immunofluorescence data of hepatitis B core 
antigen (HBcAg) stained HepaRG cells at day 10 post HBV infection (Fig. 5C and D) corresponded to these 
findings: the number of positive stained cells was severely reduced by addition of 50 µM chicago sky blue 6B, 
rosiglitazone, or zafirlukast. At similar concentrations, sulfasalazine and TRIAC only induced a mild reduction 
in positive stained cells. For HDV infection, similar results were obtained (Fig. 5E and F). To address whether the 
inhibitory effect was limited to a specific HBV genotype or cell-derived virus we tested the effect of sulfasalazine 
using patient-derived HBV (genotype B), which was also from a different genotype than the cell derived HBV 
(genotype D). Sulfasalazine showed similar inhibitory effects on HBeAg and HBsAg levels for serum-derived 
HBV as for cell-derived HBV (Supplementary Figure S3), demonstrating that the inhibitory effects on infection 
were not limited to the source or genotype of HBV.
IC50 for hNTCP-
mediated TC uptake
≥50% loss of Myrcludex B 
binding to hNTCP
Rosiglitazone 5.1 µM ≥10 µM
Zafirlukast 6.5 µM ≥1 µM
TRIAC 6.9 µM ≥10 µM
Chicago Sky Blue 6B 7.1 µM ≥1 µM
Sulfasalazine 9.6 µM ≥1 µM
Flufenamic Acid 10 µM ≥100 µM
Tolfenamic Acid 12.5 µM ≥100 µM
Toltrazuril 84.1 µM ≥10 µM
Amlexanox 91.9 µM ≥100 µM
Nifedipine 99.6 µM Not confirmed
Nelfinavir Mesylate Hydrate 134.2 µM ≥100 µM
Hydroxytacrine Maleate 4.2 mM Not confirmed
Table 1. Concentration-dependency of compounds to inhibit taurocholate uptake or Myrcludex B binding 
to human NTCP. Inhibition on taurocholate uptake was measured in U2OS-HA-hNTCP cells and IC50 values 
were calculated from increasing concentrations, ranging from 1 nM to 10 mM. Furthermore, with confocal 
microscopy for each compound it was determined at which concentration Myrcludex B binding was inhibited 
for minimally 50%. Compounds are arranged from low to high IC50 values.
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Specificity for NTCP. At the calculated IC50 value for hNTCP, chicago sky blue 6B, flufenamic acid, and 
rosiglitazone were more capable of inhibiting mouse Ntcp (Fig. 6A–C), while sulfasalazine, tolfenamic acid and 
zafirlukast were able to inhibit mouse Ntcp to a similar extent as human NTCP (Fig. 6D,E and G). TRIAC inhib-
ited NTCP-mediated bile acid transport at lower concentrations for human NTCP than for mouse Ntcp (Fig. 6F).
The apical sodium bile acid transporter (ASBT, SLC10a2), most highly expressed at the brush border of ileal 
enterocytes28, is a closely related transporter showing highest sequence similarity with NTCP1. Both NTCP and ASBT 
mediate cellular uptake of conjugated bile acids. Therefore, we examined whether the 5 most potent NTCP inhibi-
tors also affected ASBT-mediated bile acid transport. Both chicago sky blue 6B and TRIAC inhibited ASBT to a sim-
ilar extent as NTCP with a comparable decrease in taurocholate uptake at all tested concentrations (Fig. 7A and D). 
Complete absence of ASBT inhibition was shown for sulfasalazine (Fig. 7C), while rosiglitazone and zafirlukast 
inhibited ASBT less effectively and at higher concentrations than observed for NTCP (Fig. 7B and E).
Figure 2. Inhibition of human NTCP by zafirlukast. (A) Taurocholate uptake into U2OS-HA-hNTCP cells 
was reduced in the presence of zafirlukast in a concentration-dependent fashion. (B) After normalization to 
maximal NTCP inhibition, the IC50 value was calculated. N = 2–4 wells/condition, experiment was repeated 
twice. (C) Representative confocal microscopy pictures of reduced Myrcludex B-FITC fluorescence upon co-
administration with increasing amounts of zafirlukast. (D) Quantification of C, n = 3 per condition. All data are 
presented as mean ± SD.
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Discussion
From 1280 clinically-applied drugs, this study identified 5 novel NTCP inhibitors that also block HBV and HDV 
infection in vitro. Until the recent identification of compounds that directly act on the viral large surface protein29, 
most HBV/HDV entry blockers identified to date inhibit both NTCP-mediated bile acid uptake as well as infec-
tion. Partially, this is explained by historical reasons as the inhibitory effect of compounds like cyclosporine22,24, 
Figure 3. Inhibition of human NTCP by chicago sky blue 6B, rosiglitazone, sulfasalazine, and TRIAC. 
Taurocholate uptake and Myrcludex B binding was reduced to U2OS-HA-hNTCP cells in a concentration-
dependent manner by chicago sky blue 6B (A,B), rosiglitazone (C,D), sulfasalazine (E,F), and TRIAC (G,H). 
Data are presented as mean ± SD, n = 2–4 wells/condition, experiment was repeated twice. From the confocal 
studies, representative pictures are shown, n = 3 per condition.
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ezetimibe23 and irbesartan23,25 on HBV infection was assessed when the receptor NTCP was identified and their 
effect on taurocholate uptake has already been known. However, the finding that also Myrcludex B, a peptide 
mimicking the myristoylated preS1-domain of the HBV envelope L-protein, interfered with NTCP-mediated bile 
acid uptake supported the notion that the HBV and bile acid binding sites in the NTCP protein are in close prox-
imity and/or functionally intertwined3. In this study, the effects of 1280 clinically-applied compounds on both bile 
acid uptake and Myrcludex B binding were directly compared in an unbiased manner.
The screen confirmed NTCP inhibition by cyclosporin A, irbesartan, ezetimibe, and pioglitazone which had 
previously been identified as such22–26, and underscores the likelihood of a correlation between blocked bile acid 
transport and occupation of the HBV-binding site on NTCP. Reduced HBV/HDV infection in vitro was demon-
strated for chicago sky blue 6B, rosiglitazone, sulfasalazine, TRIAC, and zafirlukast. In well-established HBV/
HDV infection systems, these 5 novel inhibitors mainly act by targeting NTCP as the viral entry receptor. This is 
supported by the following two findings: 1) HDV infection was similarly affected as HBV infection. Both viruses 
share early infection events but follow different routes in viral replication5,6. 2) Cellular binding of Myrcludex B, 
the myristoylated preS1-domain of the HBV envelope L-protein9, was decreased upon co-administration with the 
5 novel inhibitors, suggesting competition for the HBV binding site on the NTCP protein.
For these 5 compounds, bile acid transport is largely inhibited at a similar concentration needed to block 
HBV/HDV infection (IC50: 5–10 µM). On the contrary, Myrcludex B has an IC50 value for bile acid transport of 
52.5 nM in primary human hepatocytes24, but blocks HBV infection at an at least 50-fold lower concentration 
(669 pM for HBsAg/83 pM for HBeAg), leaving a sufficient therapeutic range in which Myrcludex B efficiently 
blocks HBV/HDV infection while bile acid transport is largely unaffected. Another class of small molecules, 
proanthocyanidin and its analogues, were also shown to inhibit the HBV viral entry process with unaffected 
NTCP-mediated bile acid transport29. Proanthocyanidin directly targets the PreS1 region of the HBV L-protein, 
forming a novel class of anti-HBV agents.
The identification of 5 diverse novel NTCP inhibitors (chicago sky blue 6B, rosiglitazone, sulfasalazine, 
TRIAC, and zafirlukast) expands the chemical backbones to build new, more specific small molecule HBV/
HDV entry inhibitors. Recently, cyclosporin A derivatives were developed that reduced NTCP-mediated HBV 
infection in primary hepatocytes by ~60% without significantly reducing bile acid uptake30. This suggests that 
analogues of rosiglitazone, sulfasalazine, zafirlukast and perhaps TRIAC could possibly be designed that more 
potently and specifically inhibit HBV infection. From the cheminformatics analysis limits for this chemical 
space can be established (Supplementary Figs S4 and S5). As ligands with a molecular weight <300 and AlogP 
of 3 or lower were identified, one could speculate that these ligands inhibit NTCP in a manner other than com-
petitive inhibition of the bile acid binding site. Our virtual screening could not reliably identify novel active 
compounds. Unlike other bile acid transporters like OATPs, NTCP is likely not addressed by most chemotypes, 
as the percentage of actives identified in this study is much lower than in a similar screen for OATP inhibitors 
(respectively ~1% versus 7–10%)31. Previous computational models further support this observation23,25,26,32,33. 
Although they all could elucidate the requirement of hydrophobes and hydrogen bond acceptors, the exact 
number for these features varied between 3 and 1 for both in line with the current work23,26,32,33. Furthermore, 
Kramer et al.34 concluded that substrate specificity is much broader for NTCP than for the related bile acid 
transporter ASBT. Indeed, sulfasalazine, rosiglitazone, and zafirlukast, are more selective for NTCP, while chi-
cago sky blue 6B and TRIAC were as effective for ASBT as for NTCP. Chicago sky blue 6B was also identified as 
an inhibitor for vesicular glutamate transporters (VGLUTs), completely unrelated transporters, further demon-
strating its low specificity35. Although species-specific differences have been found for drugs bosentan36 and 
rosuvastatin37, only minor differences in drug specificity between mouse and human NTCP were found for 
sulfasalazine, rosiglitazone, and zafirlukast.
The usage of clinically-relevant compounds in a screen for NTCP inhibitors provides additional information 
as it seems likely that several of the hits are NTCP substrates. Myrcludex B could possibly be used in combina-
tion with such drugs, potentially leading to drug-drug interactions. In this respect, predominantly ursodeoxy-
cholic acid (UDCA) should be considered. UDCA is an unconjugated bile acid frequently used as treatment in 
Figure 4. Myrcludex B inhibits uptake of tauro-ursodeoxycholic acid. Sodium dependent tauro-
ursodeoxycholic acid uptake into U2OS-HA-hNTCP cells was reduced in the presence of Myrcludex B. 
N = 6 wells/condition, data are depicted as mean ± SD.
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 15307  | DOI:10.1038/s41598-017-15338-0
Figure 5. Inhibition of HBV and HDV infection in HepaRG cells. Rosiglitazone, sulfasalazine, TRIAC, 
zafirlukast, and irbesartan reduce both HBV (A–D) as well as HDV (E,F) infection in HepaRG cells. In a 
concentration-dependent fashion, hepatitis B extracellulair (A) and surface (B) antigen production was reduced 
by all compounds. Also, all compounds were effective in decreasing the amount of cells positively stained for 
HBcAg (C,D) and HDAg (E,F) in a concentration-dependent manner. Myrcludex B (1 µM) was included as 
positive control in all assays. Data are presented as mean ± SD, n = 3 × 2 wells/condition.
www.nature.com/scientificreports/
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cholestatic conditions, mainly primary biliary cholangitis38. Upon administration, all UDCA is converted to its 
glycine and taurine conjugated forms which mediate its hepatoprotective effects39. This therapeutic bile acid was 
found amongst the top 100 hits and Myrcludex B largely inhibited NTCP-dependent uptake of tauro-UDCA. This 
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Figure 6. Compounds also inhibit mouse NTCP. (A–G) Taurocholate uptake into U2OS cells transiently 
transfected with mouse NTCP is inhibited similarly as human NTCP by sulfasalazine (D), tolfenamic acid (E) 
and zafirlukast (G), while chicago sky blue 6B (A), flufenamic acid (B), and rosiglitazone (C) are more potent in 
inhibiting mouse NTCP. TRIAC on the other hand inhibits human NTCP more strongly (F). Data are presented 
as mean ± SD, n = 2–4 wells/condition.
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suggests that Myrcludex B co-administration might affect clearance and exposure of (conjugated) UDCA at dos-
ages that interfere with the transporter function of NTCP, which are higher than the dose required for lowering 
HBV/HDV infection.
Supplementary Table S4 describes expected serum levels of sulfasalazine, rosiglitazone, TRIAC, and zafir-
lukast upon normal therapeutic use for their intended diseases40–44. With their IC50 for NTCP in mind, sulfasala-
zine, rosiglitazone, and TRIAC are relevant to be considered as NTCP inhibitors upon normal therapeutic use, 
while treatment with zafirlukast is unlikely to induce NTCP inhibition. Notably, sulfasalazine has previously 
been shown to be a potent inhibitor of glycochenodeoxycholic acid (GCDCA)- induced apoptosis in hepato-
cytes in vitro and in the intact liver independently of its inhibiting effects on hepatocellular GCDCA uptake50, 
making it even more attractive as a candidate for therapeutic NTCP inhibition. In conclusion, from a library of 
Figure 7. Some NTCP inhibitors also reduce ASBT-mediated bile acid uptake. (A–E) Sulfasalazine (C) is 
largely ineffective in inhibiting taurocholate uptake into MDCK-ASBT cells, while chicago sky blue 6B (A), 
rosiglitazone (B), TRIAC (D), and zafirlukast (E) inhibit ASBT in a concentration-dependent fashion. Data are 
presented as mean ± SD, n = 2–3 wells/condition.
www.nature.com/scientificreports/
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clinically-applied drugs various compounds were identified that inhibit NTCP-mediated bile acid uptake and 
HBV/HDV infection in vitro. These findings could contribute to the development of novel anti-HBV and HDV 
agents.
Materials and Methods
Chemicals. The Prestwick Chemical Library® containing 1280 approved drugs as 10 mM stock solutions in 
96-well plates was purchased from Prestwick (Prestwick Chemical, Illkirch, France). Amlexanox was purchased 
from Abcam. Hydroxytacrine Maleate was obtained from Santa Cruz Biotechnology (Santa Cruz, USA). Chicago 
Sky Blue 6B, Flufenamic acid, Nelfinavir Mesylate Hydrate, Nifedipine, Rosiglitazone, Sulfasalazine, Tolfenamic 
acid, Toltrazuril, 3,3′,5-Triiodothyroacetic acid (TRIAC), Zafirlukast, and Taurocholic acid (TC) were bought 
from Sigma-Aldrich (Zwijndrecht, The Netherlands). Myrcludex B and Myrcludex B-FITC were customly syn-
thesized by Pepscan (Lelystad, The Netherlands). Hoechst 33342 was obtained from Merck Millipore (Darmstadt, 
Germany). [3H]Taurocholic acid (1 mCi/ml) and [14C]Taurocholic acid (0.05 mCi/ml) were purchased from 
PerkinElmer (Groningen, The Netherlands).
Cell culture. U2OS and MDCK cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, 
Sigma-Aldrich), supplemented with 10% FCS (Gibco), 1% L-glutamine (Lonza), and 1% penicillin/streptomycin 
(Lonza). Medium of U2OS cells stably transfected with human NTCP (U2OS-HA-hNTCP)18 or MDCK cells sta-
bly expressing human ASBT (MDCK-hASBT; kind gift of Paul Dawson)45 was supplemented with 400 µg/ml or 
350 µg/ml Geneticin (Invitrogen) respectively. Transient transfection of U2OS cells with mouse NTCP (mNTCP) 
was done with PEI reagent (Brunschwig, Basel, Switzerland). Shortly, U2OS cells were seeded one day prior to 
transfection in 24-well plates. On the day of transfection, 0.5 µg DNA was mixed with 100 µl unsupplemented 
DMEM and 3 µg/µl PEI. After 10–15 minute incubation at RT, 20 µl of the transfection mix was added to each 
24-well. Transfected cells were used in further experiments 48–72 hours later. Cell lines were passaged twice a 
week at a confluence of 80%, and incubated in a humidified atmosphere of 37 °C + 5% CO2.
HepaRG cells were cultured in Williams E medium supplemented with 10% heat-inactivated fetal calf serum, 
2 mM L-glutamine, 5 µg/ml insulin, 50 µM hydrocortisone, 50 U/ml penicillin, and 50 µg/ml streptomycin. After 
two weeks of cultivation, differentiation was induced by 1.5% dimethyl sulfoxide (DMSO) as described11.
Screening studies. We screened the Prestwick Chemical Library® in 96-well format using two different 
screening assays: a taurocholate uptake assay (using PerkinElmer ViewPlate-96 white microplate clear bottom, 
product number 6005181) and a competitive binding assay (using PerkinElmer CellCarrier-96 black, product 
number 6005550). Plates were seeded with U2OS-HA-hNTCP (92 wells) or U2OS (4 wells, background) cells at 
a density of 50.000 cells/well or 10.000 cells/well for the functional or the competitive binding assay respectively. 
Screening assays were performed at room temperature approximately 24 hours later. Drug concentration was 
10 µM and 1 µM Myrcludex B was used as positive control for NTCP inhibition and binding.
For the taurocholate uptake studies, medium was aspirated and cells were washed once with 100 µL uptake 
buffer: 5 mM KCl, 1.1 mM K2HPO4, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM D-Glucose, 10 mM HEPES and 
136 mM NaCl. For sodium free uptake buffer, NaCl was replaced by 136 mM NMDG. Buffers were set to pH 7.4, 
at room temperature. After washing, cells were pre-incubated for 10 minutes with drugs in 50 µL uptake buffer. 
Subsequently, 50 µL uptake buffer containing [14C]taurocholate was added to the wells for another 10 minutes. 
After incubation, buffer was removed and cells were washed 2x with ice-cold PBS. Cells were lysed for a minimum 
of 30 minutes in 30 µL/well 0.05% SDS in water. When lysis was complete, 120 µL MicroScint™-20 (PerkinElmer) 
was added to the wells and radioactivity was measured by liquid scintillation counting.
For the fluorescent binding assay, medium was aspirated and cells were washed once with 100 µL PBS. A 
30 minute incubation period followed in which all cells were incubated with 0.2 µM Myrcludex B-FITC with 
or without drug in 100 µL Leibovitz’s L-15 Medium (Invitrogen). Cells were washed twice with PBS and sub-
sequently 100 µL Leibovitz’s L-15 Medium was added. Of each well, 9 photos (10x objective) were taken in the 
brightfield and FITC channel using the Operetta CLS™ High-Content Imaging System (PerkinElmer).
Inhibition studies. Wildtype U2OS or U2OS-HA-hNTCP were seeded at a density of 50.000 cells in 500 µL 
complete medium in 24-well plates (VWR® Cat. Number 734–2325). For MDCK or MDCK-hASBT cells 70.000 
cells/well were plated in 24-well plates, followed by 24 hours 10 mM sodium butyrate (Sigma-Aldrich) stimulation 
the next day. Cells were used in the inhibition studies 24 hours (U2OS cell lines) or 48 hours (MDCK cell lines) 
later. Inhibition studies with mNTCP transiently transfected cells were conducted 48–72 hours after transfection.
Medium was aspirated from the wells and cells were washed once with 250 µL uptake buffer. Subsequently, 
cells were pre-incubated with drug in 150 µL uptake buffer for 10 minutes at 37 °C. Taurocholate uptake was 
initiated by addition of 100 µL uptake buffer containing taurocholate (final concentration 10 µM TC spiked with 
tritium-labeled TC) and cells were incubated for 2 minutes at 37 °C. Subsequently, cells were washed 4 times with 
ice-cold PBS and lysed with 0.05% SDS in water. Radioactivity was measured by liquid scintillation counting.
Confocal microscopy. Wildtype U2OS or U2OS-HA-hNTCP were seeded in a sterile 8-well coverslip 
bottomed chamber slide (Thermo Fisher Scientific, 155411). After 24 hours, medium was aspirated and cells 
were washed once with 300 µl Leibovitz’s L-15 Medium (Invitrogen). A 30 minute incubation period followed in 
which all cells were incubated with 0.2 µM Myrcludex B-FITC with or without drug (1, 10, 100 µM) and Hoechst 
(1/1000) in 300 µL Leibovitz’s L-15 Medium. Cells were washed twice with Leibovitz’s L-15 Medium and subse-
quently 400 µL Leibovitz’s L-15 Medium was added. Live cell fluorescent imaging was performed using a Leica 
SP8X-SMD confocal microscope with fully enclosed incubation at 37 °C. A 63x oil objective was used and images 
were captured while the cells were consecutively excited at 490 nm (FITC) 350 nm (Hoechst). ImageJ software 
(National Insititutes of Health, Bethesda, MD) was employed for data analysis.
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Cytotoxicity studies. Drug cytotoxicity was evaluated by measuring the cell viability using the water solu-
ble tetrazolium salt WST-1 (Sigma-Aldrich). Shortly, U2OS-HA-hNTCP cells were seeded at a density of 10.000 
cells/well in 96-well plates (Corning® Costar® Cat. Number 3595), and incubated for approximately 24 hours 
at 37 °C + 5% CO2. Medium was aspirated and cells were exposed to 1 µM, 10 µM, or 100 µM drug in 100 µL 
complete medium. Empty wells containing only complete medium served as background. In addition, each well 
was supplemented with 10 µL WST-1. After two hours incubation (37 °C + 5% CO2), absorbance at 450 nm and 
690 nm was measured using a Synergy HT Multi-Mode Microplate Reader (Biotek). Cell viability was calculated 
using the following formula: (A450-A690 (sample)) − (A450-A690 (background)). Viability levels higher than 80% 
were considered healthy and unaffected by the drug.
HBV/HDV infection studies. HBV was produced in HepAD38 cells46. HDV was produced by 
co-transfection of HuH7 cells with the two plasmids pSVLD3 (HDV genotype 1, kindly provided by John 
Taylor47) and pT7HB2.7 (HBV genotype D, kindly provided by Camille Sureau48). Virions in the culture superna-
tant were purified and concentrated by heparin affinity chromatography on an ÄKTApurifier FPLC system (GE 
Healthcare) and stored at −80 °C in 10% FCS.
Cells were pre-incubated for 30 min with NTCP inhibitors or Myrcludex B in medium containing 4% pol-
yethylene glycol (PEG) 8000 (Sigma-Aldrich) and 1.5% DMSO. They were then inoculated with HBV or HDV 
for 14 h at 37 °C. After inoculation, cells were washed twice with PBS and post-incubated with NTCP inhibitors 
or Myrcludex B. After 10 hours, the cells were washed twice in PBS before medium supplemented with 1.5% 
DMSO was added. Medium was exchanged every 2 days. Cells infected with HDV were fixed on day 5 post 
infection and HDV infection was quantified by immunofluorescence. To quantify the HBV infection, secretion 
of hepatitis B surface antigen (HBsAg) and hepatitis B extracellular antigen (HBeAg) into the culture superna-
tant from day 7 to 10 post infection was quantified by enzyme-linked immunosorbent assay (ELISA). The cells 
were fixed 10 days post infection and analysed by hepatitis B core antigen (HBcAg) specific immunofluores-
cence. For HBsAg-ELISA, 96 well ELISA microplates (Greiner bio-one) were coated with monoclonal mouse 
anti-HBsAg (Fitzgerald) and were then blocked with 2% BSA and 0.05% Tween-20 in PBS. After blocking, 
supernatant from infected cells was added (1:10 dilution in PBS). Plates were incubated with biotinylated mon-
oclonal mouse anti-HBsAg (Fitzgerald). The biotinylation was performed using EZ-Link Sulfo-NHS-LC-Biotin 
(ThermoFisher) as suggested by the provider. Pierce high sensitivity Streptavidin-HRP (ThermoFisher) was 
added for 30 min at 37 °C. The plates were washed three times with wash buffer (0.05% Tween-20 in PBS) after 
incubation with supernatant samples, biotinylated antibodies and Streptavidin-HRP. For HBeAg-ELISA, 96 well 
ELISA microplates were coated with monoclonal mouse anti-HBeAg (Fitzgerald) and blocked in PBS with 2% 
BSA and 0.05% Tween-20. After blocking, supernatant samples were addedMouse monoclonal anti-HBeAg-HRP 
(Fitzgerald) was added. The plates were washed three times with wash buffer after incubation with supernatant 
samples and HRP-conjugated antibodies. A dilution series of supernatant from HepAD38 cells was used as stand-
ard curve. The reaction was visualized by addition of TMB substrate (eBioscience) and stopped with 1 M H3PO4. 
Absorbance at 450 nm was measured with a PerkinElmer EnVision multilabel reader. For immunofluorescence 
HDV- and HBV-infected HepaRG cells were fixed with 4% paraformaldehyde in PBS 5 or 10 days post infection, 
respectively. Cells were permeabilized with 0.25% (vol/vol) Triton X-100 in PBS. VUDA serum anti-HDAg or 
rabbit-anti-HBcAg (DAKO) were used as primary antibodies. For quantification of infection, 4 images per treat-
ment were acquired with an epifluorescence microscope and HDAg- or HBcAg-positive cells were quantified 
with ilastik software49.
Statistics. Screen data were analysed by R software21 for statistical computing. Variance was adjusted by plate 
and data were normalized to positive and negative controls, resulting in a B-score for each sample. Follow-up 
data are provided as the mean ± standard error of the mean. Graphpad Prism 5 was used for statistical analysis. 
Significance levels were calculated using the Student’s t-test and results were considered significant at p < 0.05. 
IC50 values were calculated with non-linear regression curves.
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